Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Metastasis is a primary driver of cancer therapy failure and poor patient prognosis.
• Traditional chemotherapy exhibits limited efficacy against metastatic cells due to chemoresistance and epithelial-to-mesenchymal transition (EMT).
• Targeted therapies are essential for managing cancer as a chronic disease with manageable relapses.

Purpose of the Study:

• To provide an overview of recent advances in antimetastatic small molecule drug discovery.
• To highlight key molecular targets and drug families involved in the metastatic process.
• To inform the identification of new therapeutic targets for combating metastasis.

Main Methods:

• Review of recent scientific literature on antimetastatic small molecules.
• Focus on intracellular tyrosine kinase inhibitors, cyclin-dependent kinase inhibitors, KRAS inhibitors, and integrin antagonists.
• Analysis of the developmental stage of promising small molecule candidates.

Main Results:

• Several families of small molecules show potential as anti-metastatic agents.
• Intracellular tyrosine kinase inhibitors, CDK inhibitors, KRAS inhibitors, and integrin antagonists are key areas of research.
• Many promising small molecules are still in preclinical or early clinical development.

Conclusions:

• Targeted small molecules offer a promising avenue for overcoming limitations of traditional chemotherapy in treating metastasis.
• Continued research and development of these agents are vital for advancing cancer treatment.
• Understanding the developmental status of these drugs aids in identifying future therapeutic targets.